X4 Pharmaceuticals (XFOR) news
Recent news
X4 Pharmaceuticals Inc: Wells Fargo initiates coverage with overweight rating; price target $11
Wells Fargo has initiated coverage on X4 Pharmaceuticals Inc (XFOR) with an overweight rating and a price target of $11, signaling strong confidence in the stock’s potential. This move aligns with a broader trend of positive analyst sentiment, as 10 analysts currently cover XFOR, assigning a mean…
AInvest Wire · Jul 10, 2026X4 Pharmaceuticals appoints Kelly Gold, experienced chief financial officer, to its board of directors
AInvest Wire · Jul 1, 2026X4 Pharmaceuticals Inc <XFOR.O>: Leerink Partners initiates coverage with outperform rating; price target $12
X4 Pharmaceuticals Inc : Leerink Partners initiates coverage with outperform rating; price target $12
AInvest Wire · Jun 2, 2026X4 Pharmaceuticals Q2 2024 GAAP EPS $0.45 beats $0.01 estimate, sales $563.000k beat $278.667k estimate
AInvest Wire · Aug 8, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.